-
April 18, 2025
R & D
FDA Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis
-
March 28, 2025
R & D
Submission of New Drug Application for NS-401 (Tagraxofusp) in Japan
-
March 19, 2025
Pharmaceuticals
Launch of Uptravi® Tablets for Pediatric 0.05 mg for the Treatment of Pulmonary Arterial Hypertension in Japan
-
March 05, 2025
R & D
CAP-1002: The U.S. FDA has accepted the Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy
-
February 07, 2025
Management & Finance
Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2024
-
January 30, 2025
Corporate
Termination of Litigation with Sarepta in Japan
-
January 27, 2025
R & D
Nippon Shinyaku and AB2 BIO enter into an Option Agreement for Commercialization of Tadekinig alfa for the treatment of NLRC4 mutation and XIAP deficiency in the U.S.
-
January 23, 2025
R & D
FDA Grants Rare Pediatric Disease Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy
-
January 14, 2025
R & D
Nippon Shinyaku and REGENXBIO Enter into an Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for Mucopolysaccharidosis Diseases in the U.S. and Asia
-
January 10, 2025
R & D
NS-089/NCNP-02 for the treatment of Duchenne muscular dystrophy notice regarding publication of the results of an investigator-initiated clinical trial (First in human trial)
